Drugs for Intermittent Explosive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 38)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Guanfacine |
Approved, Investigational |
Phase 4 |
|
29110-47-2 |
3519
|
Synonyms:
29110-47-2
29110-48-3 (mono-hydrochloride)
AC1L1G4B
BPBio1_000415
BRD-K32830106-003-03-0
BSPBio_000377
C07037
C9H9Cl2N3O
CAS-29110-48-3
CHEMBL862
CID3519
D08031
DB01018
EINECS 249-442-8
Estulic
Estulic (TN)
G1043_SIGMA
Guanfacina
Guanfacina [INN-Spanish]
GUANFACINE
Guanfacine (INN)
Guanfacine [INN:BAN]
Guanfacine Monohydrochloride
Guanfacinum
Guanfacinum [INN-Latin]
|
Intuniv
L000286
L013430
Lon798
Lopac0_000519
Lopac-G-1043
LS-174236
MolPort-003-941-447
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
NCGC00015469-01
NCGC00015469-02
NCGC00015469-06
NCGC00024950-01
NCGC00024950-02
NCGC00024950-03
Prestwick0_000339
Prestwick1_000339
Prestwick2_000339
Prestwick3_000339
SPBio_002298
SPD 503
Tocris-1030
UNII-30OMY4G3MK
ZINC03872738
|
|
2 |
|
Naratriptan |
Approved, Investigational |
Phase 4 |
|
143388-64-1, 121679-13-8 |
4440
|
Synonyms:
121679-13-8
AC1L1I6A
AC-5013
Amerge, Naramig,Naratriptan
BIDD:GT0312
C07792
CHEBI:7478
CHEMBL1278
CID4440
Colatan
D08255
DB00952
InChI=1/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H
L000432
LS-83062
|
MolPort-005-932-823
Naramig
Naramig (TN)
naratriptan
Naratriptan (INN)
naratriptanum
Naratriptanum
NCGC00181786-01
N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide
S1488_Selleck
UNII-QX3KXL1ZA2
|
|
3 |
|
Sumatriptan |
Approved, Investigational |
Phase 4 |
|
103628-46-2 |
5358
|
Synonyms:
(3-[2-(dimethylamino)Ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide
(3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide
1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide
1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide
1-[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide
1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide
103628-46-2
103628-48-4 (succinate)
3-(2-(dimethylamino)Ethyl)-N-methyl-1H-indole-5-methanesulfonamide
3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide
3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide
3-[2-(dimethylamino)Ethyl]-N-methylindole-5-methanesulfonamide
3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide
AC1L1K6B
Ambap103628-46-2
BIDD:GT0248
BRD-K50938287-001-01-7
BRN 6930870
BSPBio_002304
C07319
C14H21N3O2S
CHEBI:10650
CHEMBL128
CID5358
D00451
DB00669
estradiol
GR 43175
GR 43175X
GR-43175
|
I06-0076
Imigran
Imigran (TN)
Imigran Recovery
Imitrex
Imitrex (TN)
Imitrex Oral
KS-1116
L000584
LS-83175
MLS001195659
MLS001304742
MolPort-002-885-863
NCGC00095838-01
NCGC00095838-02
NP101
SMR000596517
SPECTRUM1505372
Sumatran
sumatriptan
Sumatriptan
Sumatriptán
Sumatriptan (JAN/USP/INN)
Sumatriptan Succinate
Sumatriptanum
Sumatriptanum [INN-Latin]
Sumax
triptan
UNII-8R78F6L9VO
|
|
4 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
5 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
6 |
|
Adrenergic alpha-2 Receptor Agonists |
|
Phase 4 |
|
|
|
7 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
8 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
9 |
|
Neurotransmitter Agents |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
10 |
|
Serotonin |
|
Phase 4,Phase 3,Phase 2 |
|
50-67-9 |
5202
|
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
|
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
Antemovis
DS substance
Enteramin
Enteramine
|
|
11 |
|
Serotonin Agents |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
12 |
|
Vasoconstrictor Agents |
|
Phase 4,Phase 1,Phase 2 |
|
|
|
13 |
|
Serotonin 5-HT1 Receptor Agonists |
|
Phase 4 |
|
|
|
14 |
|
Dopamine |
Approved |
Phase 3 |
|
51-61-6, 62-31-7 |
681
|
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
hydroxytyramine
|
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
15 |
|
Risperidone |
Approved, Investigational |
Phase 3 |
|
106266-06-2 |
5073
|
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
Belivon
BIDD:GT0262
Bio-0092
BRD-K53857191-001-04-5
BRN 4891881
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
Consta, Risperdal
CPD000466323
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
Lopac-R-118
LS-134196
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
NCGC00015883-01
|
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R64,766
R-64,766
R64766
R-64766
R-64-766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
risperdone
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
risperidone
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
Sequinan
SMR000466323
SPBio_003078
Spiron
STK646402
TL8000230
UNII-L6UH7ZF8HC
|
|
16 |
|
Antipsychotic Agents |
|
Phase 3 |
|
|
|
17 |
|
Central Nervous System Depressants |
|
Phase 3 |
|
|
|
18 |
|
Dopamine Agents |
|
Phase 3 |
|
|
|
19 |
|
Dopamine Antagonists |
|
Phase 3 |
|
|
|
20 |
|
Psychotropic Drugs |
|
Phase 3,Phase 2 |
|
|
|
21 |
|
Serotonin Antagonists |
|
Phase 3 |
|
|
|
22 |
|
Tranquilizing Agents |
|
Phase 3 |
|
|
|
23 |
|
Fluoxetine |
Approved, Vet_approved |
Phase 2 |
|
54910-89-3 |
3386
|
Synonyms:
(+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+/-)-Fluoxetine
(+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine
(+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]
(+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine
3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
52341-67-0
54910-89-3
57226-07-0
59333-67-4 (hydrochloride)
AB00053774
AC-14564
AC1L1FTH
Adofen
AKOS003663021
Animex-On
Bio-0787
Biomol-NT_000152
BPBio1_000354
BPBio1_000509
BRD-A31159102-001-01-9
BRD-A31159102-003-05-6
BSPBio_000461
BSPBio_003375
C17H18F3NO
CHEBI:5118
CHEMBL41
CID3386
D00326
DB00472
Deprex
DivK1c_006819
dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
Eufor
Floxetine
Fluctin
Fluoxeren
Fluoxetin
Fluoxetina
Fluoxetina [INN-Spanish]
Fluoxetina [Spanish]
fluoxetine
Fluoxétine
fluoxetine (Prozac)
Fluoxetine (TN)
Fluoxetine (USAN/INN)
Fluoxetine [USAN:INN:BAN]
|
Fluoxetine Hcl
Fluoxetine Hydrochloride
Fluoxetinum
Fluoxetinum [INN-Latin]
Fluval
Fontex
Foxetin
HMS2090H14
KBio1_001763
KBio2_002159
KBio2_004727
KBio2_007295
KBio3_002595
KBioGR_001166
KBioSS_002159
L000931
Lilly-110140
Lopac0_000558
LS-31040
Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine
MolPort-001-683-482
NCGC00015428-10
NCGC00024879-03
NCGC00024879-04
nchembio.534-comp2
N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine
N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
NSC283480
Portal
Prestwick0_000511
Prestwick1_000511
Prestwick2_000511
Prestwick3_000511
Prozac
Prozac Weekly
Pulvules
Reconcile
Reneuron
Sarafem
SPBio_001815
SPBio_002382
SpecPlus_000723
Spectrum_001679
Spectrum2_001658
Spectrum3_001648
Spectrum4_000613
Spectrum5_001518
STK734483
TL8003595
UNII-01K63SUP8D
|
|
24 |
|
Quinidine |
Approved, Investigational |
Phase 2 |
|
56-54-2 |
441074
|
Synonyms:
(-)-Quinine
(+)-quinidine
(8R,9S)-Quinidine
(R)-(6-Methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol
(S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol
(S)-(6-Methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanol
11010-73-4
12239-42-8
128544-03-6
130-89-2
130-95-0
1407-83-6
21480-31-9
22600_FLUKA
22620_FLUKA
22620_SIGMA
500225-45-6
50-54-4
549-56-4
55980-20-6
56-54-2
572-59-8
6119-70-6
6151-39-9
6151-40-2
6183-68-2
6591-63-5
6912-57-8
6-methoxy-α-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol
72646-90-3
767303-40-2
804-63-7
840482-04-4
845886-64-8
857212-53-4
864908-93-0
875538-34-4
882741-47-1
883881-01-4
888714-03-2
890027-24-4
894767-09-0
898813-59-7
898814-00-1
898814-28-3
899813-83-3
900786-66-5
900789-95-9
906550-97-8
909263-47-4
909767-48-2
909882-78-6
910878-25-0
910880-97-6
910899-51-3
911445-75-5
918778-04-8
AB00514657
AC1L199L
AC1L1ANE
AC1L1LHL
AC1L1R7Y
AC1L3RNZ
AC1L9AHT
AC1L9AHW
AC1LCUGN
AC1LDI43
AC1LDI46
AC1MBNAI
AC1MHDEF
AC1MHUCH
AC1MHWS7
AC1MI1Q5
AC1NSV55
AC1NSV58
AC1NSZYR
AC1NSZYU
AC1NUNML
AC1NUNMO
AC1NX8JM
AC1O56R7
AC1O7EE0
AC1O7GNZ
AC1OAH7Z
AC1OCD5W
AC1OCD62
AC1OFCPL
AC1Q4EZ5
AC1Q4EZ6
AC1Q58AF
Aflukin
Apo-Quinidine
AR-1A4833
AR-1H2065
Auriquin
BB_NC-0697
beta-Quinine
BIB1110
BIDD:GT0144
Biquin Durules
bmse000511
C06526
C06527
C20H24N2O2
Cardioquin
CCRIS 5755
CCRIS 672
CHEBI:111177
CHEBI:15854
CHEBI:28593
CHEMBL170
CHEMBL21578
CHEMBL576997
CHEMBL601807
CHEMBL97
Chinidin
Chinidine
chinidinum
Chinidinum
Chinin
Chinine
chininum
CID10448938
CID1065
CID25522
CID2728270
CID3000825
|
CID3032576
CID3034034
CID3036746
CID441073
CID441074
CID5317111
CID5317112
CID5320867
CID5320868
CID5484444
CID5484450
CID5748152
CID5953
CID637552
CID6453100
CID6602154
CID6604605
CID667448
CID667449
CID6857801
CID6916033
CID6916036
CID7048767
CID8549
CID94175
CID9967055
Cin-Quin
CIN-QUIN
Coccinine
Coco-Quinine
Conchinin
Conchinine
Conquinine
CPD000857275
D08458
D08460
DB00468
DB00908
Duraquin
Epiquinidine
FT-0082277
GNF-Pf-180
GNF-Pf-5423
GNF-PF-5459
HMS1304I22
HMS1607A11
HMS1989J09
HMS2089E05
HSDB 225
HSDB 2501
I14-3348
I14-3397
IBS-L0034250
IDI1_000134
KBio1_000134
KBio2_001392
KBio2_003960
KBio2_006528
KBio3_001551
Kinidin
Kinidin (TN)
KST-1A1085
L001278
Lopac-Q-0875
Lopac-Q-1250
LS-141252
LS-187236
LS-194958
LS-221
LS-4562
LT00645788
MLS001304041
MLS001335913
MLS001335914
NCI60_004320
NCI-C56246
NINDS_000134
Novoquinidin
NSC 192949
NSC 5362
NSC131458
NSC192949
NSC5362
NSC667852
OR28880
Pitayin
Pitayine
Q0006
Q3625_SIGMA
Quinact
Quinaglute
Quinaglute Dura-Tabs
Quinalan
Quinate
Quinatime
Quindan
Quindine
Quinicardine
Quinidex
Quinidex Extentabs
quinidina
Quinidina
quinidine
Quinidine Gluconate
Quinidine Sulfate
Quiniduran
Quinimax
quinina
Quinine
Quinine Dab
Quinora
Quin-Release
Quniacridine
RH01857
SAM002264644
SB01652
SMP1_000254
SMR000718748
SMR000857275
SPBio_001375
SPBio_002379
ST056282
TCMDC-131239
TNP00086
α-(6-methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol
β-quinine
|
|
25 |
|
Arginine Vasopressin |
|
Phase 1, Phase 2 |
|
|
|
26 |
|
Coagulants |
|
Phase 1, Phase 2 |
|
|
|
27 |
|
Hemostatics |
|
Phase 1, Phase 2 |
|
|
|
28 |
|
Hormones |
|
Phase 1, Phase 2 |
|
|
|
29 |
|
Natriuretic Agents |
|
Phase 1, Phase 2 |
|
|
|
30 |
|
SRX246 |
|
Phase 1, Phase 2 |
|
|
|
31 |
|
Vasopressins |
|
Phase 1, Phase 2 |
|
|
|
32 |
|
Antidepressive Agents |
|
Phase 2 |
|
|
|
33 |
|
Antidepressive Agents, Second-Generation |
|
Phase 2 |
|
|
|
34 |
|
Cytochrome P-450 CYP2D6 Inhibitors |
|
Phase 2 |
|
|
|
35 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 2 |
|
|
|
36 |
|
Neurotransmitter Uptake Inhibitors |
|
Phase 2 |
|
|
|
37 |
|
Serotonin Uptake Inhibitors |
|
Phase 2 |
|
|
|
38 |
|
Quinidine gluconate |
|
Phase 2 |
|
|
|
Interventional clinical trials:
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder |
Completed |
NCT02048241
|
Phase 4 |
Intuniv |
2 |
Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order |
Terminated |
NCT00282165
|
Phase 4 |
naratriptan;placebo |
3 |
Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. |
Completed |
NCT00399698
|
Phase 3 |
Risperdal |
4 |
Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder |
Completed |
NCT02055638
|
Phase 1, Phase 2 |
SRX246;Placebo |
5 |
Psychotherapy for Intermittent Explosive Disorder |
Completed |
NCT00667212
|
Phase 2 |
|
6 |
A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder |
Completed |
NCT00078754
|
Phase 2 |
Fluoxetine;Divalproex;Placebo |
7 |
A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IED |
Completed |
NCT00127400
|
Phase 2 |
|
8 |
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder |
Recruiting |
NCT03420222
|
Phase 2 |
AVP-786;Placebo |
|